These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12003409)

  • 21. Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy.
    Ecker KW; Stallmach A; Löffler J; Greinwald R; Achenbach U
    Dis Colon Rectum; 2005 Feb; 48(2):237-42. PubMed ID: 15714248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.
    D'Haens G; Verstraete A; Cheyns K; Aerden I; Bouillon R; Rutgeerts P
    Aliment Pharmacol Ther; 1998 May; 12(5):419-24. PubMed ID: 9663720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
    Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
    Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
    Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
    Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
    Weigand K; Wagner-Thiessen E; Stolte M
    Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease.
    Dilger K; Alberer M; Busch A; Enninger A; Behrens R; Koletzko S; Stern M; Beckmann C; Gleiter CH
    Aliment Pharmacol Ther; 2006 Feb; 23(3):387-96. PubMed ID: 16422998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe adrenal insufficiency complicating budesonide therapy for Crohn's disease.
    Berkelhammer C; Trabolsi M; Andrejic J; Yasmeen T
    Inflamm Bowel Dis; 2011 Apr; 17(4):1053-4. PubMed ID: 20629105
    [No Abstract]   [Full Text] [Related]  

  • 30. [Budesonide and inflammatory bowel disease].
    Gomollón F; Hinojosa J; Nos P
    Gastroenterol Hepatol; 1999 Dec; 22(10):525-32. PubMed ID: 10650668
    [No Abstract]   [Full Text] [Related]  

  • 31. [What determines corticosteroid choice in a specific patient?].
    García Sánchez V; Iglesias Flores E; Gómez Camacho F
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():27-37. PubMed ID: 19087861
    [No Abstract]   [Full Text] [Related]  

  • 32. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?].
    Lanyi B; Dienes HP; Kruis W
    Dtsch Med Wochenschr; 2005 Aug; 130(34-35):1944-7. PubMed ID: 16123897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Budesonide for chronic inflammatory bowel diseases].
    Nguyen HN
    Dtsch Med Wochenschr; 1998 Oct; 123(42):1258-9. PubMed ID: 9809049
    [No Abstract]   [Full Text] [Related]  

  • 35. [Paradigmatic shift in drug treatment of Crohn disease].
    Munck LK
    Ugeskr Laeger; 2005 Aug; 167(33):3013. PubMed ID: 16109239
    [No Abstract]   [Full Text] [Related]  

  • 36. In Brief: Extended-release budesonide (Ortikos) for Crohn's disease.
    Med Lett Drugs Ther; 2020 Nov; 62(1610):176. PubMed ID: 33429405
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral budesonide approved for active Crohn's disease.
    Thompson CA
    Am J Health Syst Pharm; 2001 Dec; 58(23):2229. PubMed ID: 11763799
    [No Abstract]   [Full Text] [Related]  

  • 38. Microalbuminuria is not a valuable marker for relapse in Crohn's disease.
    Horjus CS; van Oijen MG; Davids AH; Naber AH; de Jong DJ
    Digestion; 2011; 83(1-2):41-5. PubMed ID: 20847562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
    Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.
    Bar-Meir S; Chowers Y; Lavy A; Abramovitch D; Sternberg A; Leichtmann G; Reshef R; Odes S; Moshkovitz M; Bruck R; Eliakim R; Maoz E; Mittmann U
    Gastroenterology; 1998 Oct; 115(4):835-40. PubMed ID: 9753485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.